July 6, 2020 / 11:37 AM / a month ago

BRIEF-Sesen Bio Inc Received Product-Specific Pediatric Waiver From European Medicines Agency For Vicineum

July 6 (Reuters) - Sesen Bio Inc:

* SESEN BIO INC - ON JULY 3, RECEIVED A PRODUCT-SPECIFIC PEDIATRIC WAIVER FROM THE EUROPEAN MEDICINES AGENCY FOR VICINEUM

* SESEN BIO - PIP WAIVER FROM THE EMA APPLIES TO VICINEUM ACROSS ALL SUBSETS OF THE PEDIATRIC POPULATION FOR THE TREATMENT OF UROTHELIAL CARCINOMA

* SESEN BIO - PIP WAIVER IS ANTICIPATED IN EARLY 2021, WITH POTENTIAL APPROVAL ANTICIPATED IN EARLY 2022. Source text for Eikon: [ID: bit.ly/3gsEsHW] Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below